Applied Filters
LSIPR 50 2017: Yoshinori Ohsumi
Yoshinori Ohsumi was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2017: Michael Salzmann
Michael Salzmann was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2017: David Tomko
David Tomko was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2017: Marcus Dalton
Marcus Dalton was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
LSIPR 50 2017: Steve Bossone
Steve Bossone was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
LSIPR 50 2017: Andrea Borucki
Andrea Borucki was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.
LSIPR 50 2017: Eduardo Andretto
Eduardo Andretto was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
Case report: diagnostics in Germany
In September 2016, the German Federal Supreme Court decided a patent case that could have a major impact on companies working in the diagnostics field. Joachim Wachenfeld of Vossius & Partner reports.
The road ahead: potential challenges facing CRISPR/Cas patents
Past successes by trailblazers in other biotechnological fields could assist potential patentees navigate legal bumps along the road to IP protection for CRISPR-related inventions, as Patricia Carson and Ashley Ross of Kirkland & Ellis describe.
Aslan: fighting cancer head-on
Based in Singapore, biotech company Aslan Pharmaceuticals specialises in developing new treatments to fight cancers that are prevalent in Asia, often requiring licensing deals to ensure it is fully equipped. LSIPR spoke to general counsel Ben Goodger to find out more.
